Apellis Pharmaceuticals I... (APLS)
24.28
0.00 (0.00%)
At close: Mar 28, 2025, 3:59 PM
23.76
-2.13%
Pre-market: Mar 31, 2025, 06:00 AM EDT
Apellis Pharmaceuticals Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
| Revenue | 709.95M | 396.59M | 75.42M | 66.56M | 250.65M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 117.72M | 58.51M | 5.64M | 5.2M | 25.05M | 288.02M | 127.92M | 50.77M | n/a | n/a | n/a | n/a |
| Gross Profit | 592.23M | 338.08M | 69.79M | 61.36M | 225.6M | -288.02M | -127.92M | -50.77M | n/a | n/a | n/a | n/a |
| Operating Income | -236.39M | -517.12M | -594.61M | -536.28M | -213.73M | -288.02M | -127.92M | -50.77M | -27.28M | -46.57M | -11.29M | -4.03M |
| Interest Income | 12.77M | 20.93M | 8.91M | 418K | 4.16M | 5.11M | 2.96M | n/a | n/a | n/a | n/a | n/a |
| Pretax Income | -196.72M | -526.5M | -651.5M | -746M | -343.03M | -304.71M | -127.5M | -51.01M | -27.12M | -46.52M | -11.23M | -3.96M |
| Net Income | -197.88M | -528.63M | -652.17M | -746.35M | -344.87M | -309.82M | -127.5M | -51.01M | -27.12M | -46.52M | -10.79M | -3.96M |
| Selling & General & Admin | 501.05M | 500.81M | 277.16M | 176.77M | 139.4M | 67.05M | 22.64M | 10.46M | 4.3M | 6.36M | 2.91M | 1.71M |
| Research & Development | 327.57M | 354.39M | 387.24M | 420.87M | 299.92M | 220.97M | 105.29M | 40.3M | 22.98M | 13.73M | 8.38M | 2.32M |
| Other Expenses | n/a | n/a | -288K | 1.36M | -501K | -175.31K | -110.76K | 11.54K | 157.71K | 6.28K | 62.46K | 68K |
| Operating Expenses | 828.62M | 855.2M | 664.4M | 597.64M | 439.32M | 288.02M | 127.92M | 50.77M | 27.28M | 20.09M | 11.29M | 4.03M |
| Interest Expense | 40.39M | 29.58M | 32.63M | 13.24M | 29.94M | 5.28M | 2.51M | 96.92K | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 946.35M | 913.71M | 670.03M | 602.84M | 464.37M | 288.02M | 127.92M | 50.77M | 27.28M | 20.09M | 11.29M | 4.03M |
| Income Tax | 1.16M | 2.13M | 669K | 352K | 1.84M | 5.11M | -533.32K | 250.61K | -27.28M | -26.54M | -443.34K | n/a |
| Shares Outstanding (Basic) | 123.9M | 118.68M | 106.11M | 84.42M | 75.16M | 62.23M | 54.4M | 13.87M | 18.09M | 18.09M | 18.09M | 18.09M |
| Shares Outstanding (Diluted) | 123.9M | 118.68M | 106.11M | 84.42M | 75.16M | 62.23M | 54.4M | 13.87M | 18.09M | 18.09M | 18.09M | 18.09M |
| EPS (Basic) | -1.6 | -4.45 | -6.15 | -8.84 | -4.59 | -4.98 | -2.34 | -3.68 | -1.5 | -2.57 | -0.6 | -0.22 |
| EPS (Diluted) | -1.6 | -4.45 | -6.15 | -8.84 | -4.59 | -4.98 | -2.34 | -3.68 | -1.5 | -2.57 | -0.6 | -0.22 |
| EBITDA | -236.39M | -495.21M | -617.39M | -731.27M | -312.23M | -298.83M | n/a | -50.9M | 157.71K | 6.4M | -11.29M | -4.02M |
| Depreciation & Amortization | 1.8M | 1.7M | 1.49M | 1.49M | 859K | 595.45K | 127.92M | 11.94K | 27.28M | 52.97M | 6.59K | 6.26K |